Semaglutide Treatment: What a Course of Therapy Looks Like

Published May 25, 2026Updated May 27, 2026Last reviewed May 25, 2026

For the broader cluster context, see the semaglutide diet and food hub.

Author: HealthRX Editorial Team Medically reviewed by: Dr. Mark Halpern, MD (Internal Medicine, Obesity Medicine) Last clinical review: May 2026

Compounded semaglutide is not FDA-approved. This article is patient education and does not replace consultation with a licensed clinician.

When Rachel, a 41-year-old dental hygienist in Tucson, started compounded semaglutide at 0.25 mg in January 2025, she assumed the drug would mostly handle things. "I figured I'd inject once a week and the weight would come off," she told her clinician at a three-month check-in. She'd lost 14 pounds by then, which was fine, but her hair was thinning and she was exhausted by 2 p.m. every day. Her protein intake, when she actually tracked it for a week, averaged 38 grams. For a woman her size, that was roughly a third of what the clinical literature recommends. The medication was working. Her nutrition wasn't keeping up.

Rachel's story is common enough to be almost boring, and that's exactly the point. Semaglutide treatment isn't just a prescription. It's a course of therapy with phases, nutritional demands, common mistakes, and real decisions about how long to continue. This article walks through what that actually looks like.

This guide sits inside the broader Semaglutide Diet and Food cluster, which is part of the compounded semaglutide pillar guide.

The Evidence This Article Draws On

A quick note on sourcing, because it matters. The clinical evidence base for semaglutide as a molecule comes from a series of large randomized trials: SUSTAIN, STEP-1, STEP-3, STEP-4, LEADER, and SELECT. These trials tested branded products (Wegovy, Ozempic). Compounded semaglutide uses the same active ingredient, prepared by a licensed compounding pharmacy under a clinician prescription, but it is not FDA-approved and has not been independently tested in randomized trials at the same scale. The regulatory status, oversight, and supply chain for compounded preparations are distinct from the branded products.

That distinction matters. It also doesn't erase the fact that the molecule is the same molecule. The trial data tells us what semaglutide does in the body. Compounding tells us how it's prepared and delivered. Those are different questions.

Why Every Calorie Has to Work Harder

Here's the thing about appetite suppression: it's a double-edged achievement. Semaglutide reduces caloric intake. That's the design. But when a patient who used to eat 2,200 calories a day drops to 1,300, whatever she does eat has to carry more nutritional weight per bite. Think of it like downsizing from a four-bedroom house to a studio apartment. You can't keep all the furniture. You have to be ruthless about what stays.

Protein adequacy, fiber, and micronutrient density aren't nice-to-haves during therapy. They're the difference between weight loss that preserves lean mass and weight loss that strips it.

The STEP-3 trial is instructive here. It paired semaglutide with a structured lifestyle intervention (calorie target, behavioral counseling, 30 minutes of daily activity). The active arm in STEP-3 lost more weight on average than the active arm in STEP-1, which used the medication without that structured support. The trial doesn't prove diet alone explained the gap. But it strongly supports what obesity medicine clinicians already observe in practice: nutrition guidance changes outcomes.

Most clinical references converge on a per-day target of 1.2 to 1.6 grams of protein per kilogram of body weight, 20 to 30 grams of fiber, and adequate hydration. Within that frame, the specific foods are flexible. Lower-fat, lower-volume preparations tend to be best tolerated during titration. Spicy and fried foods are common triggers for early-therapy nausea.

What a Day on Therapy Actually Looks Like

A practical day on semaglutide is different from a day without it, in ways that are subtle until you pay attention. Hunger arrives later. It plateaus faster. Fullness signals hit sooner and harder. Most patients settle into two meaningful meals and one or two small ones. Protein lands first; vegetables and starches follow. Fluid is harder to remember and easier to underdo (a pattern that sneaks up on people around week six).

The most common practical mistakes, repeated across patient forums and clinician reports alike:

Skipping protein early in the day, then trying to cram it all into dinner
Relying on liquid calories (smoothies, juices) that don't trigger the same fullness signaling
Eating a large evening meal after a low-intake morning, which compounds GI discomfort

Each of these has a boring, simple correction. Front-load protein at breakfast. Eat solid food. Spread meals more evenly. Nobody wants to hear it, but it works.

The Three Phases of a Treatment Course

A typical semaglutide treatment course breaks into three phases, and understanding them upfront prevents a lot of confusion later.

Phase one: Titration. This takes roughly four months under the standard dosing schedule, with gradual increases from 0.25 mg to the target dose. The purpose is tolerability, not dramatic results. Side effects (nausea, constipation, occasional fatigue) tend to cluster here and typically improve with time. Patients who expect rapid weight loss during titration often feel discouraged prematurely.

Phase two: Maintenance dosing. This is the open-ended stretch during which weight loss continues at a slower pace and lifestyle patterns (ideally) become more durable. Patients who finish their first six months on therapy typically describe a different relationship to food than they had before. Portion calibration is easier. Cravings are less directional. The work of building lasting eating patterns starts during therapy, not after it ends.

Phase three: The long-term decision. Continue indefinitely? Taper to a lower dose? Discontinue? This is a clinical decision shaped by response, tolerability, comorbidities, and patient preference. STEP-1, STEP-3, STEP-4, SELECT, and LEADER each contribute data to this framework, but there's no fixed endpoint that applies universally. Patients should expect periodic clinical review of progress, side effects, labs as appropriate, and adherence patterns throughout therapy.

My opinionated take: most patients underestimate how important phase three planning is. They treat semaglutide like an antibiotic, something you take until the problem goes away, when the better analogy is a blood pressure medication, something you may need to continue or carefully manage your way off of.

What Happens When You Stop

STEP-4 documented what happens when the drug goes away. Patients who switched from active semaglutide to placebo at week 20 experienced partial weight regain over the following 48 weeks. The chronic biology of weight regulation reasserts itself without pharmacologic support, in the same way hypertension trends back toward baseline when you stop the antihypertensive.

This isn't failure. It's physiology. And it's exactly why the conversation about duration of therapy needs to happen early, not when the prescription runs out.

Misconceptions That Keep Circulating

A few persistent misunderstandings show up in patient questions so regularly they're worth addressing directly.

"Compounded semaglutide is the same as Wegovy, just cheaper." The active ingredient is the same. The regulatory status is not. Compounding pharmacies operate under a different framework with different oversight. Compounded preparations are not FDA-approved. This matters, and patients should understand what it means for their specific situation.

"If I'm not nauseous, it's not working." The trial data don't support this. Patients in STEP-1 and STEP-3 with mild GI tolerability and patients with pronounced GI symptoms both achieved meaningful weight loss. Side effect intensity is not a proxy for efficacy.

"The medication does the work." STEP-3 (medication plus structured lifestyle intervention) outperformed STEP-1 (medication alone) on mean weight loss. Lifestyle is additive. For durable outcomes, it's not optional.

"Once I stop, I'll be right back where I started." Partial regain is documented, but "partial" is the key word. And patients who build durable habits during therapy tend to retain more of their progress than those who relied on pharmacology alone. (This is clinical observation more than trial-proven fact, but the pattern is consistent enough to mention.)

The Clinician Relationship Matters More Than the Brand

One more thing worth saying plainly. The clinician relationship matters more than the brand of program. A program that supports honest clinical conversation, responds to side effects with appropriate dose adjustments, and provides clear follow-up between refills produces better outcomes than a program with glossy marketing and weaker clinical infrastructure. If your provider doesn't know your current dose or hasn't asked about your protein intake, that's a signal.

Adjacent Reading

Where This Fits

This article is part of the Semaglutide Diet and Food cluster. For a broader treatment of the molecule, the regulatory pathway, the 503A and 503B compounding framework, and the clinical evidence base, the compounded semaglutide pillar guide is the primary reference on this site.

Frequently Asked Questions

Does diet matter on semaglutide?

Diet matters more on semaglutide, not less. Appetite suppression means patients eat fewer calories overall, which makes the composition of those calories disproportionately important, especially for protein, fiber, and micronutrient adequacy.

How much protein is appropriate?

Most clinical references cited for GLP-1 patients converge on 1.2 to 1.6 grams of protein per kilogram of body weight per day, adjusted for activity and clinical context.

What foods are best tolerated early in therapy?

During titration, lower-volume, lower-fat, higher-protein meals tend to be best tolerated. Spicy, fried, and very rich foods are commonly reported as triggers for nausea or reflux.

How long does a typical treatment course last?

There is no universal answer. Titration takes roughly four months, and maintenance dosing continues as long as clinically appropriate. The decision to continue, taper, or discontinue is individualized and should involve ongoing clinical review.

What happens if I stop taking semaglutide?

STEP-4 documented partial weight regain over 48 weeks after patients switched from active drug to placebo. The degree of regain varies, and patients who maintain lifestyle changes during therapy tend to retain more of their progress.

Is compounded semaglutide the same as Wegovy?

The active ingredient is the same molecule. The regulatory status is different. Compounded semaglutide is prepared by a licensed compounding pharmacy under a clinician prescription and is not FDA-approved. The clinical evidence base for the molecule comes from trials of the branded products.

Does nausea mean the medication is working?

No. Trial data from STEP-1 and STEP-3 show that patients with varying levels of GI side effects achieved meaningful weight loss. Side effect severity does not predict clinical response.

Compliance and Authorship

This article references the STEP-1, STEP-3, STEP-4, SUSTAIN, SELECT, and LEADER clinical trial programs where appropriate. It is intended as patient education and does not replace consultation with a licensed clinician.